Literature DB >> 15075521

Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients.

Eugenia Negredo, Josep Ribalta, Raimon Ferré, Juliana Salazar, Celestino Rey-Joly, Guillem Sirera, Lluís Masana, Bonaventura Clotet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15075521     DOI： 10.1097/00002030-200403260-00017

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  12 in total

1.  FABP4 plasma levels are increased in familial combined hyperlipidemia.

Authors:  Anna Cabré; Iolanda Lázaro; Montserrat Cofán; Estibaliz Jarauta; Núria Plana; Angel L Garcia-Otín; Juan F Ascaso; Raimón Ferré; Fernando Civeira; Emilio Ros; Lluís Masana
Journal:  J Lipid Res       Date:  2010-05       Impact factor: 5.922

2.  Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients.

Authors:  Sofia A Pereira; Teresa Branco; Rita M Côrte-Real; Isabel Germano; Fátima Lampreia; Umbelina Caixas; Emília C Monteiro
Journal:  Br J Clin Pharmacol       Date:  2006-05       Impact factor: 4.335

3.  Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients.

Authors:  S A Pereira; J R Batuca; U Caixas; T Branco; J Delgado-Alves; I Germano; F Lampreia; E C Monteiro
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

Review 4.  Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.

Authors:  Emma Kaplan-Lewis; Judith A Aberg; Mikyung Lee
Journal:  Curr HIV/AIDS Rep       Date:  2016-10       Impact factor: 5.071

Review 5.  Hormonal contraception and HIV-positive women: metabolic concerns and management strategies.

Authors:  Julie Womack; Susan Richman; Phyllis C Tien; Margaret Grey; Ann Williams
Journal:  J Midwifery Womens Health       Date:  2008 Jul-Aug       Impact factor: 2.388

6.  Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis.

Authors:  Susan L Rosenkranz; Kevin E Yarasheski; Michael F Para; Richard C Reichman; Gene D Morse
Journal:  Metab Syndr Relat Disord       Date:  2007-06       Impact factor: 1.894

7.  The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men.

Authors:  David Wohl; Rebecca Scherzer; Steven Heymsfield; Michael Simberkoff; Stephen Sidney; Peter Bacchetti; Carl Grunfeld
Journal:  J Acquir Immune Defic Syndr       Date:  2008-05-01       Impact factor: 3.731

8.  Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution.

Authors:  Pl Williams; Jw Wu; Se Cohn; Sl Koletar; Ja McCutchan; Rl Murphy; Js Currier
Journal:  HIV Med       Date:  2009-02-08       Impact factor: 3.180

9.  Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.

Authors:  Michelle A Floris-Moore; Katie Mollan; Aimee M Wilkin; Marc A Johnson; Angela Dm Kashuba; David A Wohl; Kristine B Patterson; Owen Francis; Catherine Kronk; Joseph J Eron
Journal:  Antivir Ther       Date:  2015-08-11

10.  Long-term body composition and metabolic changes in HIV-infected children switched from stavudine to tenofovir and from protease inhibitors to efavirenz.

Authors:  Valentina Fabiano; Vania Giacomet; Alessandra Viganò; Giorgio Bedogni; Sara Stucchi; Lucia Cococcioni; Stefano Mora; Gian Vincenzo Zuccotti
Journal:  Eur J Pediatr       Date:  2013-05-01       Impact factor: 3.183
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.